chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Urinary Tract infection set in within 48 hours of covid shot. Recovered Then got second round of shot and the same thing happened again.
Myalgia, Arthralgia, UrticariaPruritus, chills Narrative:
Pts DOB was not recognized during screening processes and vaccine was administered.  Called and spoke w/ Pts mother (caregiver) and confirmed that although and MD told her to get the children vaccinated, Moderna has not been approved yet for this age group.   Vaccine dose #2 will not be given until further information is released
Lowered body temperature 30 min after dose, left hand began to itch approx. 45 minutes, both hands itching & swelling, then feet within hour.  Total lose of vision within 90 min followed by fainting approx 10 minutes later.  Fainted at check-in desk of emergency room
Fungal rash on body occurred exactly 2-3 after vaccination - attempted to clear with diflucin, OTC antifungal (did not help)  Within one week, ovaries started to ache and discovered chlamydia with no sexual contact within last 2 years. Never tested before covid vaccine nor had issues with ovaries pain before vaccine. Previous partner tested negative for chlamydia. Also, never had excema flare up or continuous fungal infection before vaccination.   Feel that bacteria/ fungus has been overflowing in body since vaccination.   Fungus and STI cleared in three months   As of today, ovary aches and skin rashes are back with absolutely no change to diet, medication, or sexual contact.
Rash on left leg like dozens of bug bites, slight rash on right leg, fatigue, headache, body aches.
My lips and my tounge swelled. Also around my face swelled one day. I'm not sure but it felt like my throat might have swelled a little one night.
Pt experienced three slight dizzy spells about 1.5 hours post vax. Each spell lasted about 20 seconds approximately 30 minutes apart.
R arm swollen, red and hot from elbow to shoulder. Pt c/o itching. Tx'd with augmentin xr.
nosebleed on 11/7/07 after receiving FluMist.  Bled approximately 10 min from right nostril.  moderate amount of bleeding.
Site: Redness at Injection Site-Mild, Systemic: Allergic: Itch (specify: facial area, extremeties)-Mild, Systemic: Allergic: Rash (specify: facial area, extremeties)-Mild
Received First is on December 28. Later that evening severe muscle aches, runny nose, migraine and joint pain. Fatigue nausea and diarrhea. Minimal pain at injection site. No edema or redness at injection site.
Pain developed in right arm at injection site. Pain very slowly diminished for 10 days. First day temperature of 101.3F.  Very debilitating, making it difficult to dress and to sleep.  Hand to take anti anxiety drugs to help sleep for 8 days.   I had COVID -19 and was hospitalized from Nov.16 to Dec. 4 2020.  Then 2 weeks in bed before able to walk downstairs.  Not a pleasant experience!
Hives around neck and different locations on upper body. Lasted two days. Took pharmacist recommended Benadryl.
This spontaneous report was received from a pharmacist concerning a 63 year old female patient. The patient's historical condition and concurrent condition were not reported. Drug reaction-allergies included penicillin and sulfas (unspecified). On 26-JUN-2018, the patient was vaccinated with PNEUMOVAX 23 injection, right arm, lot # R006465 and expiry date 24-OCT-2019 (strength, dose, route and frequency were not reported) for prophylaxis. Concomitant therapies included zoster vaccine (unspecified) (manufacturer unknown). On the same date, the patient experienced pain and swelling with a 2 inches red strip at the injection site after vaccination with PNEUMOVAX 23, therefore she sought medical attention with the pharmacist. The adverse events did not represent a significant disability or incapacity, the patient did not require hospitalization and no treatment was given to her. It was also reported that no laboratory diagnostics-studies were performed. The outcome of vaccination site pain, vaccination site erythema and vaccination site swelling was not recovered. The causality assessment between PNEUMOVAX 23 and the aforementioned events was not reported.
arm feels like it will fall off; This spontaneous case was reported by a patient and describes the occurrence of LIMB DISCOMFORT (arm feels like it will fall off) in a 54-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.     It was reported that patient had no allergies and medical history. .    On 09-Jun-2022, the patient received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form and first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced LIMB DISCOMFORT (arm feels like it will fall off). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. At the time of the report, LIMB DISCOMFORT (arm feels like it will fall off) outcome was unknown.            Patient height was 5'10.  Patient had no concomitant medications.  Patient was neither tested nor diagnosed with COVID in the past.   Reporter did not allow further contact
Information has been received from a health professional concerning a 25 year old female with a history of food allergies who on 06-JUN-2007 was vaccinated intramuscularly in the left deltoid with her first dose of Gardasil (lot# 0469U). On 07-AUG-2007 the patient was vaccinated intramuscularly in the left deltoid with her second dose of Gardasil. On 08-AUG-2007 the patient experienced ringing in the left ear which still persists. The patient had extensive testing and follow up with specialists to find out the cause of the ringing in her left ear. The patient had a normal Brain MRI and a normal ENT check up. The patient was treated with a water pill, VALTREX and MEDROL Pak. The patient sought medical attention in the office. Additional information has been requested.
Patient received 0.5ml of the (NDC 80777-0279-05) Moderna vaccine for 6 months- 5 years instead of the Moderna Bivalent 0.5ml dose. Patient has had a sore arm and is tired. Since this was the monovalent vaccine at the appropriate dose (still 50mcg) we are waiting 2 months and if the patient still wants, giving the Moderna Bivalent vaccine.
12 hours later woke up with pruritus, 36 hours later pruritus increased, with hives all over the body. Largest hive on arm, at least 4 inches in diameter. No other problems.
Came to office 1 week after immunizations were given with New onset Type 1 DM with sugar of 977. 8/30/07-records received-for DOS 7/13-7/15/07- DC DX: Diabetic ketoacidosis resolved. Type I diabetes new onset. Dehydration resolved. Hyperkalemia, resolved. Two week history of polyuria, polydipsia, nocturia, dry mouth and blurry vision, 12 pound weight loss for the last month or so. in ED blood sugar over 1000. C/O not feeling well, weak, decreased appetite, nausea and vomiting. 1/11/2010 Patient has type I DM.
Employee has erythema and warmth at site of second Hep-B immunization, some localized pain and tenderness.
p/vax pt devel swelling & pain at inj site;also devel fever; MD Dx cellulitis & rx biaxin
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 71-year-old female patient received BNT162b2 (BNT162B2 NOS), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Known allergies: Sulfa" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "Treatment of COVID-19". Therapeutic measures (Paxlovid treatment) were taken as a result of drug ineffective, covid-19.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Pt adm Hep B vax (recomb) on 5OCT90 & 5NOV90; On 6DEC90 pt recvd third dose of vax which does not follow the six month protocol; No futher details were provided;
Pt reported shortness of breath episode and was concerned as it was similar onset as ADR associated w contrast dye allergy. Pt was able to speak easily without breathing interference so RPh administered 25mg diphenhydramine orally at 1252pm. 911 and store management team engaged.  2-3 minutes later pt reported tightness in chest increasing so RPh administered epinephrine 0.3mg IM in right thigh.  EMS arrived immediately after and assessed pt. She felt better right away. All vitals were normal so pt declined treatment from EMS. She stayed at the pharmacy for observation another 20 minutes. She continued to feel fine and left to go shopping and then home. RPh called pt at home approx. 3:30pm and pt stated her breathing was normal but that she had a headache that she was treating at home.
PATIENT WAS GIVEN MODERNA COVID BIVALENT VACCINE 2 WEEKS POST GETTING THE SAME VACCINE.  PHYSICIAN WAS INFORMED IMMEDIATELY
Local reaction in place of injection: redness and swelling down to elbow, pain and itching, hot to touch. General symptoms: fever - 102, body aches, sore joints, chills.
Patient had made an appointment for a dose of Janssen. Patient received the dose of Janssen, but system would only allow Pfizer vaccine to be selected. On further investigation, system showed that PT received a dose of Pfizer vaccine on 8/7/21. On the paper screening form that we used, he attested that he had not received a previous dose of any COVID vaccine.
Sore arm; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Sore arm) in an elderly female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Crohn's disease.    There was no reported medical history.    On an unknown date, the patient received third dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular) 1 dosage form and ADALIMUMAB (HUMIRA) (Subcutaneous) 40 mg /0.4 ml. On an unknown date, the patient experienced PAIN IN EXTREMITY (Sore arm). At the time of the report, PAIN IN EXTREMITY (Sore arm) was resolving.            On an unknown date, patient received  Dose 1 and Dose 2 of Moderna COVID-19 vaccine via Intra-muscular route.  The reporter's causality for the event of Sore arm with Adalimumab Solution for Injection was Not provided.  The other causality for the event of Sore arm with Adalimumab Solution for Injection and Moderna COVID-19 vaccine (Elasomeran) was Not provided.  No concomitant medication reported. No treatment medication reported.
h/a frontal lobe; lt arm pain distal & proximal radiating up lt side of neck to head; dizziness & lt arm weakness;
On the 04FEB2021 the same thing happen. The redness was smaller about 1.5 inch to 2.5 inches; Itchy and then it went away; Red about 2 inches wide 3 inches long; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PRURITUS (Itchy and then it went away), VACCINATION SITE RASH (Red about 2 inches wide 3 inches long) and VACCINATION SITE RASH (On the 04FEB2021 the same thing happen. The redness was smaller about 1.5 inch to 2.5 inches) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 004M20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event. Concomitant products included CALCIUM CARBONATE, COLECALCIFEROL (VITAMIN D 2000) for an unknown indication.    On 28-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 28-Jan-2021, the patient experienced VACCINATION SITE PRURITUS (Itchy and then it went away) and VACCINATION SITE RASH (Red about 2 inches wide 3 inches long). On 04-Feb-2021, the patient experienced VACCINATION SITE RASH (On the 04FEB2021 the same thing happen. The redness was smaller about 1.5 inch to 2.5 inches). The patient was treated with OXYMETAZOLINE HYDROCHLORIDE (CLARITIN ALLERGIC) at an unspecified dose and frequency. At the time of the report, VACCINATION SITE PRURITUS (Itchy and then it went away), VACCINATION SITE RASH (Red about 2 inches wide 3 inches long) and VACCINATION SITE RASH (On the 04FEB2021 the same thing happen. The redness was smaller about 1.5 inch to 2.5 inches) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment details included Claritin.
A report has been received from a Health Professional concerning a 3 year old, Female subject, who had been receiving Nasal FLUMIST QUADRIVALENT (Intranasal). FLUMIST QUADRIVALENT (Intranasal) started on 07-Jan-2014. It was reported that forty two patients were administered with expired FLUMIST QUADRIVALENT which was started on 07-Jan-2014. The outcome of the event gave expired FLUMIST QUADRIVALENT is unknown. The report was considered to be non-serious.
Fever; Achy muscles; Achy joints; Fatigue; Malaise; This is a spontaneous report from a non-contactable consumer, the patient. A 35-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0165) via an unspecified route of administration in the left arm on 02May2021 14:00 (at the age of 35-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medications included ibuprofen (MANUFACTURER UNKNOWN), fenugreek, prenatal vitamins and loratadine (MANUFACTURER UNKNOWN). The patient did not receive any other vaccines within four weeks prior of vaccination. The patient previously took the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0165) via an unspecified route of administration in the left arm on 11Apr2021 at 14:00 (at the age of 35-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 03May2021 at 01:00, 11 hours after the second dose of vaccination, the patient experienced fever, achy muscles, achy joints, fatigue and malaise. The clinical outcomes of the events fever, achy muscles, achy joints, fatigue and malaise was resolved on 04May2021 after lasting for about a day.  No follow-up attempts are possible; information about lot/batch number cannot be obtained
Rash; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of RASH (Rash) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced RASH (Rash). At the time of the report, RASH (Rash) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were provided.  Treatment medications were unknown.   Reporter did not allow further contact
Diarrhea, Chills, Hives, Itchy Eyes, Runny Nose, Shortness of breath. I took some Benadryl because the reaction felt similar to an allergic reaction. I?m doing lots better now.
This spontaneous report as received from an physician assistant via a company representative refers to a 80 year old female patient. The patient's medical history, concurrent conditions or concomitant therapies were not reported. On an unknown date, the patient was vaccinated with ZOSTAVAX, subcutaneous for prophylaxis (dose, application site and lot # were not reported). On an unknown date, the patient developed a full blown of shingles less than 24 hours after receiving ZOSTAVAX. The patient's outcome was unknown. Upon internal review, the event full blown of shingles was considered to be medically significant. Additional information has been requested.
1st injection was tolerated. the second injection months later immediately developed flu-like symptoms MUSCLE AND JOINT PAIN. 3rd day symptoms of a pancreatic flare-up.  My condition became extremely painful forcing me to the ER. During the time from injection prior to going to ER I was consuming low fat diet and water which caused extreme pain and spasms of the abdomen with pain radiating to my back. Tests were taken including  CT scan they came back negative for pancreatitis. the ER doctor suggested it might be constipation. I was not constipated and was regular every day. I still continue to have symptoms of pancreatitis. I do receive multiple steroid injections that have lowered my immune system drastically.  The last steroid injection was two months prior to my 2cd vaccine injection while experiencing a bad cold. Not tested for covid No tests available. Another side effect I noticed rapid hair loss on my face (eyebrows eyelashes) and rapid hair loss on scalp. Overall depleted health with bedridden status.
arm swelling to the point I could not use it. It has now been 29 hours and movement is improving slightly. I went to bed at 630pm (4 hours after injection) and slept all night...woke for 3 hours and slept all day. I've experienced body, joint aches. This was my 1st dose.  I'm hoping tomorrow is better. I read that the Moderna dose may be higher than what is needed. I am only 120lbs. I am afraid to get the second dose because I've read the 2nd dose is usually more intense reaction for most people.
5min post vax pt went into anaphylactic shock;it was reported that pt exp itching, flushing face, barking cough, n/v & BP dropped;given epi SC in rt arm, cetirizine hcl, cromolyn sodium, flunisolide& proventil;30min later pt pale & sleepy;
Patient Received Havrix (Peds Hep A) vaccine on 6/16/2009.  Developed fevers to 101+ farenheit that evening.  Had acute mental status changes the next day for less than 30 mins.  Patient was seen in office within 30 mins of neurological changes and symptoms had completely resolved.  Neuorlogical exam nonfocal.
Information regarding Flumist (2003-2004 Formula) (influenza virus vaccine, live intranasal (2003-2004 Formula) (influenza virus vaccine, live intranasal (2003-2004 formula) nasal solution (frozen) was received from a consumer regarding a 6-year old female patient who experienced fever of 101.2, cough and phlegm. At 6 years of age, the patient received the first dose on 12-Dec-2003. Medical History: The patient's concurrent illness includes eczema. Product Details: Indication for Flumist (2003-2004 Formula) was immunization. Product was administered on 12-Dec-2003. Dose regimen was 0.5 mL (intranasal). Concomitant Therapy: Concomitant therapy included Elidel (pimecrolimus). Event Details: The patient received Flumist 0.5 mL on 12-Dec-2004 with no immediate adverse effects; she did not receive a booster dose. On 09-Feb-2004 the patient experienced fever of 101.2 (pyrexia) and cough (cough). She was treated with Pedia Care and Advil. On 10-Feb-2004 the patient's temperature was "normal" but she still had a little cough with "phlegm" (throat secretion increased). No additional information was available at the time of this report.  FOLLOW UP: information was received from a physician attributing the patient's fever to an ear infection and reporting administration of a second dose of Flumist with no reaction. On 24FEB2004, the pt received her second dose of Flumist with no reaction.
Flu like symptoms after 2nd primary dose; This spontaneous case was reported by a patient and describes the occurrence of INFLUENZA LIKE ILLNESS (Flu like symptoms after 2nd primary dose) in a 57-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 04-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 01-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 01-Apr-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced INFLUENZA LIKE ILLNESS (Flu like symptoms after 2nd primary dose). On 03-Apr-2021, INFLUENZA LIKE ILLNESS (Flu like symptoms after 2nd primary dose) had resolved. Concomitant medication information was not provided by the reporter.  Treatment information was not provided by the reporter.   This case was linked to MOD-2022-549161, MOD-2022-549162 (Patient Link).
pt exp achy joints, gen malaise, rash; 24MAY flushed face, hands, arms & rash on back; achy joint, jaw temp locked;
Patient stated 2 days after she received the vaccine she started c/o hives, very itchy all over the body, left eye swollen shut, no fever/body aches or chills, no n/v or sob, very fatigue and tired. As of 4/6/21 the patient is feeling better and the hives and itching are subsiding and getting better everyday.  Patient went to  ER  on Thursday 3/25/21. ER MD gave an rx for Prednisone 20mg but stated to not use if she doesn't need it but to continue taking the Benadryl. Patient is also using the Benadryl cream and Hydrocortisone spray (both are helpful). MD ER called the CDC and he as informed by the CDC that the patient shouldn't receive the 2nd dose of Pfizer and it was recommended to get the JJ vaccine.
Fever 100.3..red..swollen arm..area size 6x5.raised..dark appearance..painful to move
01/21/2021 @ 03:00 AM: Started feeling dizzy, nausea, headache, body ache, and vomiting. Was referred to the emergency room by duty nurse.
Information has been received on 31-OCT-2018 regarding a case in litigation concerning a female patient (age unknown). The patient's medical history, concurrent conditions and concomitant medication use were not provided. The patient's healthcare provider, recommended and/or prescribed ZOSTAVAX to the patient for its intended purpose of permanent prevention and protection against shingles and zoster-related conditions. On or about 24-OCT-2014, a pharmacist administered the ZOSTAVAX vaccine to the patient. The patient was inoculated with the ZOSTAVAX vaccine to obtain permanent prevention and protection against shingles and zoster-related injuries. On or about November 2015, the patient was treated by a physician for shingles. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX vaccine, and suffered serious physical, emotional, and economic damages as a result of the patient's injuries. The patient used the ZOSTAVAX vaccine for the permanent prevention of shingles and zoster-related injuries. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX vaccine. As a direct and proximate result of the ZOSTAVAX vaccine, the patient has and will continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs include care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; lost wages; loss of earnings capacity; and other losses and damages. Additional information has been requested.